As the year comes to a close, we’re taking a moment to reflect on what has been an exciting and transformative year for TetraKit. From major funding milestones to scientific breakthroughs and team growth, 2025 has laid a strong foundation for what’s ahead.
This year, we:
– Were selected for the highly prestigious EIC Accelerator (EICA), one of Europe’s most competitive innovation funding programs, an important endorsement of our breakthrough technology, scientific excellence, and commercial potential.
– Kicked-off Eurostars and Grand Solutions funding, expanding our non-dilutive funding portfolio and strengthening international collaboration.
– Demonstrated preclinical efficacy of ¹³¹I-DualFAPi and successfully labeled DualFAPi with ²¹¹At for the first time, advancing our targeted alpha therapy program.
– Gained full access to a newly established, fully operational astatine laboratory, enabling in-house astatine-based radiopharmaceutical development.
– Established our first partnership collaboration with 3BP, already achieving promising results.
– Expanded our team from 9 to 14 employees.
– Attended leading international conferences in nuclear medicine, strengthening visibility and industry engagement.
TetraKit wishes everyone a Merry Christmas and a happy holiday season. We’re looking forward to many more collaborations and opportunities in 2026.
